MDT

87.61

-0.94%↓

VEEV

282.58

-0.57%↓

A

118.79

-2.22%↓

WBA

11.52

+0.44%↑

HQY

100.84

-1.1%↓

MDT

87.61

-0.94%↓

VEEV

282.58

-0.57%↓

A

118.79

-2.22%↓

WBA

11.52

+0.44%↑

HQY

100.84

-1.1%↓

MDT

87.61

-0.94%↓

VEEV

282.58

-0.57%↓

A

118.79

-2.22%↓

WBA

11.52

+0.44%↑

HQY

100.84

-1.1%↓

MDT

87.61

-0.94%↓

VEEV

282.58

-0.57%↓

A

118.79

-2.22%↓

WBA

11.52

+0.44%↑

HQY

100.84

-1.1%↓

MDT

87.61

-0.94%↓

VEEV

282.58

-0.57%↓

A

118.79

-2.22%↓

WBA

11.52

+0.44%↑

HQY

100.84

-1.1%↓

Search

Harvard Bioscience Inc

Cerrado

SectorSalud

0.44 -2.22

Resumen

Variación precio

24h

Actual

Mínimo

0.44

Máximo

0.45

Métricas clave

By Trading Economics

Ingresos

-50M

-50M

Ventas

-2.8M

22M

Margen de beneficio

-231.193

Empleados

330

EBITDA

-43M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+566.67% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

4.1M

20M

Apertura anterior

2.66

Cierre anterior

0.44

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

113 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Harvard Bioscience Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jul 2025, 23:55 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Adquisiciones, fusiones, absorciones

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Charlas de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Charlas de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Adquisiciones, fusiones, absorciones

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Charlas de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Comparación entre iguales

Cambio de precio

Harvard Bioscience Inc Esperado

Precio Objetivo

By TipRanks

566.67% repunte

Estimación a 12 meses

Media 3 USD  566.67%

Máximo 3 USD

Mínimo 3 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harvard Bioscience Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.3 / 0.3401Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

No Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

113 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.